Healthcare News

With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner...

TORONTO and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing...

Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by...

Total of 618 patients randomized Topline 12-week data expected in Q1 2027 MILAN and MORRISTOWN, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA:...

Seasoned legal executive brings more than 20 years of experience in strategic transactions, corporate governance, finance and corporate legal operations

SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at...

Published data validates ZIP12-mediated zinc signaling as a novel driver of pulmonary vascular remodeling and supports a differentiated therapeutic approach targeting underlying disease biology Phase...

Phase 2 trial to evaluate SUN-627, a potent, highly-selective, brain-penetrant, oral allosteric TYK2 inhibitor, in people with progressive forms of MS Novel brain-penetrant TYK2 inhibitor offers...

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a...

BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA...